JP2008542219A - 疼痛処置法 - Google Patents

疼痛処置法 Download PDF

Info

Publication number
JP2008542219A
JP2008542219A JP2008512757A JP2008512757A JP2008542219A JP 2008542219 A JP2008542219 A JP 2008542219A JP 2008512757 A JP2008512757 A JP 2008512757A JP 2008512757 A JP2008512757 A JP 2008512757A JP 2008542219 A JP2008542219 A JP 2008542219A
Authority
JP
Japan
Prior art keywords
phenyl
compound
pyrimidin
ylamino
methoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008512757A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008542219A5 (https=
Inventor
ワブニトズ フィリップ
スチャウエルテ ヘイケ
スツムム ガブリエレ
フレイタグ ジョアチム
Original Assignee
インゲニウム ファーマシューティカルズ ジーエムビーエイチ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by インゲニウム ファーマシューティカルズ ジーエムビーエイチ filed Critical インゲニウム ファーマシューティカルズ ジーエムビーエイチ
Publication of JP2008542219A publication Critical patent/JP2008542219A/ja
Publication of JP2008542219A5 publication Critical patent/JP2008542219A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/336—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/396—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having three-membered rings, e.g. aziridine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2008512757A 2005-05-25 2006-05-24 疼痛処置法 Pending JP2008542219A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US68434505P 2005-05-25 2005-05-25
PCT/EP2006/004924 WO2006125616A2 (en) 2005-05-25 2006-05-24 Pyrimidine-based cdk inhibitors for treating pain

Publications (2)

Publication Number Publication Date
JP2008542219A true JP2008542219A (ja) 2008-11-27
JP2008542219A5 JP2008542219A5 (https=) 2009-07-09

Family

ID=36940712

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008512757A Pending JP2008542219A (ja) 2005-05-25 2006-05-24 疼痛処置法

Country Status (4)

Country Link
US (1) US20090221581A1 (https=)
EP (1) EP1901747A2 (https=)
JP (1) JP2008542219A (https=)
WO (1) WO2006125616A2 (https=)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014506908A (ja) * 2011-03-02 2014-03-20 リード ディスカバリー センター ゲーエムベーハー 薬学的活性化二置換ピリジン誘導体
JP2015526479A (ja) * 2012-08-23 2015-09-10 ヴィロスタティクス・ソチエタ・ア・レスポンサビリタ・リミタータＶｉｒｏＳｔａｔｉｃｓ ｓｒｌ 新規な４，６−二置換アミノピリミジン誘導体
JP2016533366A (ja) * 2013-10-17 2016-10-27 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ Ｄｎａ−ｐｋ阻害剤
JP2018533606A (ja) * 2015-11-13 2018-11-15 デウン ファーマシューティカル カンパニー リミテッド ナトリウムチャネル遮断剤
JP2020537661A (ja) * 2017-10-17 2020-12-24 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ ピリミジンＴＢＫ／ＩＫＫεインヒビター化合物およびそれらの使用
JP2023537586A (ja) * 2020-08-07 2023-09-04 南京薬石科技股▲フン▼有限公司 Ｃｄｋ９阻害剤およびその使用

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1763526B1 (en) * 2004-06-28 2009-06-24 Bayer Schering Pharma AG 4,6-disubstituted pyrimidines and their use as protein kinase inhibitors
US20080188524A1 (en) * 2006-10-25 2008-08-07 Martin Augustin Methods of treating pain
WO2008065155A1 (en) * 2006-11-30 2008-06-05 Ingenium Pharmaceuticals Gmbh Cdk inhibitors for treating pain
JP5566880B2 (ja) * 2007-04-24 2014-08-06 インゲニウム ファーマシューティカルズ ジーエムビーエイチ プロテインキナーゼの阻害剤としての４，６−二置換アミノピリミジン誘導体
WO2008129070A1 (en) * 2007-04-24 2008-10-30 Ingenium Pharmaceuticals Gmbh Inhibitors of protein kinases
US8389521B2 (en) * 2007-04-24 2013-03-05 Ingenium Pharmaceuticals Gmbh Inhibitors of protein kinases
WO2008132138A1 (en) * 2007-04-25 2008-11-06 Ingenium Pharmaceuticals Gmbh Derivatives of 4,6-disubstituted aminopyrimidines
CA2693588C (en) * 2007-07-13 2015-11-17 Icagen, Inc. Sodium channel inhibitors
AU2008309517B2 (en) * 2007-10-12 2013-03-14 Astrazeneca Ab Inhibitors of protein kinases
HU0900798D0 (en) 2009-12-21 2010-03-01 Vichem Chemie Kutato Kft 4-phenylamino-pyrimidine derivatives having protein kinase inhibitor activity
JP6378171B2 (ja) 2012-04-24 2018-08-22 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ Ｄｎａ−ｐｋ阻害剤
SI3527563T1 (sl) 2013-03-12 2022-01-31 Vertex Pharmaceuticals Incorporated Inhibitorji DNA-PK
RU2675270C2 (ru) 2013-10-17 2018-12-18 Вертекс Фармасьютикалз Инкорпорейтед Сокристаллы и содержащие их фармацевтические композиции
RU2758669C2 (ru) 2016-09-27 2021-11-01 Вертекс Фармасьютикалз Инкорпорейтед Способ лечения рака с применением сочетания днк-поражающих агентов и ингибиторов днк-пк
US12157730B2 (en) 2019-03-19 2024-12-03 Voronoi Inc. Heteroaryl derivative, method for producing same, and pharmaceutical composition comprising same as effective component
AU2020240382B2 (en) 2019-03-19 2022-08-25 Voronoi Inc. Heteroaryl derivative, method for producing same, and pharmaceutical composition comprising same as effective component

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005009980A1 (en) * 2003-07-22 2005-02-03 Neurogen Corporation Substituted pyridin-2-ylamine analogues
WO2005026129A1 (en) * 2003-09-15 2005-03-24 Gpc Biotech Ag Pharmaceutically active 4,6-disubstituted aminopyrimidine derivatives as modulators of protein kinases

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9319568D0 (en) * 1993-09-22 1993-11-10 Euro Celtique Sa Pharmaceutical compositions and usages
EP1373257B9 (en) * 2001-03-29 2008-10-15 Vertex Pharmaceuticals Incorporated Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases
US20040106647A1 (en) * 2002-06-28 2004-06-03 Schneider Michael D. Modulators of Cdk9 as a therapeutic target in cardiac hypertrophy
US7576085B2 (en) * 2002-09-23 2009-08-18 Schering Corporation Imidazopyrazines as cyclin dependent kinase inhibitors
CA2503715A1 (en) * 2002-10-30 2004-05-21 Merck & Co., Inc. Kinase inhibitors
TW200614993A (en) * 2004-06-11 2006-05-16 Akzo Nobel Nv 4-phenyl-pyrimidine-2-carbonitrile derivatives

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005009980A1 (en) * 2003-07-22 2005-02-03 Neurogen Corporation Substituted pyridin-2-ylamine analogues
WO2005026129A1 (en) * 2003-09-15 2005-03-24 Gpc Biotech Ag Pharmaceutically active 4,6-disubstituted aminopyrimidine derivatives as modulators of protein kinases

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014506908A (ja) * 2011-03-02 2014-03-20 リード ディスカバリー センター ゲーエムベーハー 薬学的活性化二置換ピリジン誘導体
US9242937B2 (en) 2011-03-02 2016-01-26 Bayer Intellectual Property Gmbh Pharmaceutically active disubstituted pyridine derivatives
JP2015526479A (ja) * 2012-08-23 2015-09-10 ヴィロスタティクス・ソチエタ・ア・レスポンサビリタ・リミタータＶｉｒｏＳｔａｔｉｃｓ ｓｒｌ 新規な４，６−二置換アミノピリミジン誘導体
JP2018197233A (ja) * 2012-08-23 2018-12-13 ヴィロスタティクス・ソチエタ・ア・レスポンサビリタ・リミタータＶｉｒｏＳｔａｔｉｃｓ ｓｒｌ 新規な４，６−二置換アミノピリミジン誘導体
JP2016533366A (ja) * 2013-10-17 2016-10-27 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ Ｄｎａ−ｐｋ阻害剤
JP2018533606A (ja) * 2015-11-13 2018-11-15 デウン ファーマシューティカル カンパニー リミテッド ナトリウムチャネル遮断剤
JP2020537661A (ja) * 2017-10-17 2020-12-24 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ ピリミジンＴＢＫ／ＩＫＫεインヒビター化合物およびそれらの使用
JP7284161B2 (ja) 2017-10-17 2023-05-30 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング ピリミジンＴＢＫ／ＩＫＫεインヒビター化合物およびそれらの使用
JP2023537586A (ja) * 2020-08-07 2023-09-04 南京薬石科技股▲フン▼有限公司 Ｃｄｋ９阻害剤およびその使用
JP7537002B2 (ja) 2020-08-07 2024-08-20 南京薬石科技股▲フン▼有限公司 Ｃｄｋ９阻害剤およびその使用

Also Published As

Publication number Publication date
US20090221581A1 (en) 2009-09-03
WO2006125616A3 (en) 2007-04-19
WO2006125616A2 (en) 2006-11-30
EP1901747A2 (en) 2008-03-26

Similar Documents

Publication Publication Date Title
JP2008542219A (ja) 疼痛処置法
JP5693951B2 (ja) プロテインキナーゼの阻害剤
JP5379787B2 (ja) プロテインキナーゼの阻害剤
US20080188524A1 (en) Methods of treating pain
JP5566880B2 (ja) プロテインキナーゼの阻害剤としての４，６−二置換アミノピリミジン誘導体
KR20240021884A (ko) 암을 치료하기 위한 parp 억제제와 조합된 atr 억제제의 용도
CN101801362A (zh) 用于治疗病症的方法和组合物
CN102548983A (zh) 作为单酰甘油脂肪酶抑制剂的杂芳族和芳族哌嗪基氮杂环丁基酰胺
JP2009543768A (ja) 医薬組み合わせ
JP2013521324A (ja) プロテインキナーゼの阻害剤
JP5291700B2 (ja) 血管新生阻害薬及び使用方法
JP2007517800A (ja) 糖尿病および肥満を処置するためのグリコーゲンホスホリラーゼインヒビターとしての（３−オキソ−３，４−ジヒドロ−キノキサリン−２−イル−アミノ）−ベンズアミド誘導体および関連化合物
NO342153B1 (no) Forbindelsen 1-(3-(2-(1-benzotiofen-5-yl)etoksy)propyl)azetidin-3-ol, eller et salt derav for behandling eller forebygging av sykdom
JP2017014224A (ja) 帯状疱疹関連痛の急性期疼痛の予防又は治療剤
JP5566879B2 (ja) プロテインキナーゼの阻害剤
ITMI20130647A1 (it) Composti con attività inibente sulle sirtuine
CN101289444B (zh) 一种嘧啶衍生物及其医药用途
JP2009514941A (ja) 血小板減少症を治療する化合物および方法
US20080153822A1 (en) Methods of treating pain
BRPI0619416A2 (pt) derivados de pirimidilaminobenzamida para o tratamento da neurofibromatose
AU2005205914A1 (en) Combination of organic compounds
JP2002302458A (ja) 併用薬
JP4221294B2 (ja) 摂食亢進剤および食欲不振症治療剤
EP1907004A2 (en) Combination of a renin inhibitor and an insulin secretion enhancer or an insulin sensitizer
WO2010029995A1 (ja) 疼痛治療剤

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090520

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20090520

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20111115

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120210

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120217

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120514

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20120821